Immunosuppression Clinical Trials

21 recruiting

Immunosuppression Trials at a Glance

25 actively recruiting trials for immunosuppression are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 4 with 8 trials, with the heaviest enrollment activity in Paris, Marseille, and Dijon. Lead sponsors running immunosuppression studies include University Hospital, Limoges, Children's Hospital of Fudan University, and Central Adelaide Local Health Network Incorporated.

Browse immunosuppression trials by phase

Treatments under study

About Immunosuppression Clinical Trials

Looking for clinical trials for Immunosuppression? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immunosuppression trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immunosuppression clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 25 trials

Recruiting

Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)

Healthy VolunteerImmunosuppressionPeriodontal Disease+1 more
National Institute of Dental and Craniofacial Research (NIDCR)700 enrolled1 locationNCT01568697
Recruiting
Not Applicable

Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients

ImmunosuppressionVaccine Response Impaired
Central Adelaide Local Health Network Incorporated160 enrolled1 locationNCT06262776
Recruiting
Phase 2

Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy

Immunosuppression
Linda Cendales50 enrolled1 locationNCT02310867
Recruiting
Phase 4

Combined Immunosuppression for Pediatric Crohn's Disease

Crohn DiseaseImmunosuppressionChildren, Only+1 more
Children's Hospital of Fudan University128 enrolled1 locationNCT05043870
Recruiting
Phase 4

Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)

Liver TransplantationImmunosuppression
University Hospital, Limoges162 enrolled18 locationsNCT06354179
Recruiting
Phase 1Phase 2

Immune Tolerance Induction After Liver Transplantation

Liver TransplantationEnd Stage Liver DiseaseImmune Tolerance+6 more
University of California, Los Angeles12 enrolled1 locationNCT07269041
Recruiting
Phase 2Phase 3

Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo

Post-aggressive ImmunosuppressionAdult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C
Assistance Publique - Hôpitaux de Paris170 enrolled2 locationsNCT06694740
Recruiting
Not Applicable

Vascularized Composite Bladder Allograft Transplantation

Bladder DysfunctionNeurogenic BladderImmunosuppression
University of Southern California5 enrolled1 locationNCT05462561
Recruiting
Not Applicable

Fibroscan to Guide Post Transplant Immunosuppression Minimization

Immunosuppression
University of Alberta50 enrolled1 locationNCT07206277
Recruiting

Pathological Myeloid Activation After Sepsis and Trauma

SepsisImmunosuppressionTrauma Injury+1 more
University of Florida255 enrolled1 locationNCT05616130
Recruiting
Phase 3

Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression

Sustained Immunosuppression
University Hospital, Limoges326 enrolled23 locationsNCT06774235
Recruiting
Early Phase 1

Tolerance Through Mixed Chimerism (Sip-Tego)

Kidney FailureTransplant Recipient (Kidney)Immunosuppresion+2 more
Tatsuo Kawai, MD, PhD12 enrolled1 locationNCT06972069
Recruiting
Phase 4

Effectiveness and Cost-effectiveness of a Pre-emptive Genotyping Strategy in Patients Receiving Tacrolimus

Kidney Disease, ChronicImmunosuppressionTransplant Recipient (Kidney)
Instituto de Investigación Hospital Universitario La Paz114 enrolled1 locationNCT06701825
Recruiting
Phase 4

Immunoinflammatory Regulation of Esketamine in Septic Patients

SepsisInflammatory ResponseEsketamine+1 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology100 enrolled2 locationsNCT04843982
Recruiting
Phase 4

Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients

COVID-19ImmunosuppressionVaccine Response Impaired
University of California, Davis50 enrolled1 locationNCT05060991
Recruiting
Phase 3

Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS

Fungal InfectionImmunosuppressionDisseminated Histoplasma Capsulatum Infection+1 more
Federal University of Health Science of Porto Alegre279 enrolled5 locationsNCT05814432
Recruiting

Registry of Vaccine Responses in Immune Compromised Patients

Immunosuppression
Laure Pittet, MD-PhD300 enrolled1 locationNCT06463119
Recruiting
Phase 4

Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs

Immunosuppression
Edward Geissler300 enrolled9 locationsNCT06268769
Recruiting

The Transplant Cohort of the German Center for Infection Research

InfectionsImmunosuppressionTransplant Complication+1 more
Technical University of Munich3,000 enrolled1 locationNCT06346665
Recruiting
Phase 4

Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.

Heart FailureMyocarditisImmunosuppression+2 more
Medical University of Warsaw100 enrolled1 locationNCT04654988